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Abstract
The G-protein-coupled receptors (GPCRs, also called seven-transmembrane 
receptor, 7TMRs, or heptahelical receptor) are a conserved family of seven trans-
membrane receptors which are essential not only in the healthy heart and blood 
vessels but also in for treatment and therapy of cardiovascular disease and failure. 
Heart failure is a global leading cause of morbidity and death and as such under-
standing 7TMRs, their functions, structures and potential for therapy is essential. 
This review will investigate the roles of the receptors in the healthy functioning 
cardiovascular system, and in cardiac disorders with an emphasis in cardiomyopa-
thy. It will also explore the role of autoimmunity and autoantibodies against the 
G-protein-coupled receptors in cardiomyopathy.
Keywords: angiotensin, adrenoreceptors, cardiomyopathy, heart disease, 
endothelin-1, muscarinic receptors, vascular
1. Introduction
The 7 transmembrane receptors (7TMRs) also known as G-protein coupled 
receptors (GPCRs) constitute the largest family of plasma membrane receptors. The 
superfamily of 7TMRs includes receptors for hormones, neurotransmitters and ion 
channels, and is critical to mediate physiological and cellular processes [1, 2].
Composed of seven transmembrane hydrophobic alpha (α) helices joined by 
three intracellular and three extracellular loop structures, a cytoplasmic carboxyl 
terminus and an extracellular amino terminus (Figure 1), 7TMRs signal by stimu-
lating heterotrimeric G proteins following the presentation of an agonist to the 
receptor [3]. Agonist binding at the 7TMR extracellular region initiates the forma-
tion of a G protein. Guanosine diphosphate (GDP) is released from the G protein 
in exchange for guanosine triphosphate (GTP). The GTP bound α subunit disas-
sociates from the βγ dimer, both of which activate several effectors such as adenylyl 
cyclase, phospholipases and ion channels [3]. The Gα subunit can be categorised in 
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to sub groups Gαs, Gαi, Gαq/11 and Gα12/13 [3]. The Gα subunits and the Gβγ dimer 
deriving from the heterotrimeric G protein can combine with downstream effector 
molecules such as adenylyl cyclase or phospholipase C to control cellular signalling 
pathways involving secondary messengers [3]. Examples of secondary messengers 
include cyclic adenosine monophosphate (cAMP), inositol-1,4,5-trisphosphate (IP3) 
and diacylglycerol (DAG) which elicit cellular and physiological responses [4].
2. Cardiovascular effects of 7TMRs and therapeutic drug targets
7TMRs are the target for a large proportion of therapeutic drugs, currently 
encompassing more than 30% of prescription medications [5] which directly or 
indirectly alter cellular signalling mechanisms.
2.1 Adrenoreceptors (β-adrenergic receptors)
Adrenergic receptors (ARs; also known as adrenoreceptors) are a class of 7TMRs 
located in the heart and vasculature and are responsible for relaying sympathetic 
nervous system (SNS) messages into cardiovascular reactions [1]. The neurotrans-
mitters norepinephrine (NE) and epinephrine (Epi), which originate from the SNS, 
exert their effects on cardiac cells and tissues by binding to adrenoreceptors [6]. A 
number of adrenoreceptor subgroups are present in the mammalian heart, includ-
ing three α1-ARs, three α2-ARs and three β-ARs (β1, β2 and β3) [6].
β-Adrenergic receptors (β-ARs) are the most important and one of the most 
frequently studied receptors belonging to the family of G-protein coupled receptors 
[7]. There are three subtypes of β-ARs: β1, β2 and β3, activation of which regulates 
important cardiovascular functions [7, 8]. The β1-ARs are characterised mainly 
for the heart, β2-ARs for blood vessels and β3-ARs for adipose tissue [9]. Within the 
vasculature the predominant subtype is β2-AR, which is 65–70% homologous to 
β1- and β3-ARs [8]. The agonists that bind with all three subtypes of β-ARs are the 
hormones adrenaline and noradrenaline, which help regulate cardiovascular and 
pulmonary function [10, 11].
Human genes encoding the β2-ARs are without introns and have been mapped to 
chromosome 5q31–32 [12]. The β-ARs consist of 413 amino acid residues, approxi-
mately 46.5 kDa [8]. There are three domains of β2-ARs: The extracellular domain, 
Figure 1. 
General structure of a seven transmembrane receptor (7TMR)/G protein coupled receptor (GPCR). 
Extracellular loops 1–3 (EL1–3) and intracellular loops (IL1–3) connecting the 7 transmembrane helices 
(TM1–7). NH2▬N-terminal chain and COOH▬C-terminal chain.
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the transmembrane domain responsible for the ligands binding and the intracellular 
domain, which interacts with G protein and kinases such as β-ARK [13]. β2-ARs 
occur mainly in the lungs, where their presence has been shown in airway smooth 
muscle (30,000–40,000 per cell), epithelial and endothelial cells, type II cells and 
mast cells [8]. Moreover β2-ARs are in heart, kidney and blood vessels—mainly 
arterioles [8, 14].
As in the other G-receptors the signalling pathway of β2-ARs, which bind with 
a hormone ligand includes three basic steps: Receptor binding, G protein activa-
tion and effector system activation. β2-ARs may occur in two forms, activated and 
inactivated [6]. The binding of β-ARs agonist with β2-receptor activates the path-
way in which Gs coupled proteins are involved. The stimulation of G proteins causes 
guanosine triphosphate (GTP) to bind to the α-subunit (Gsα) that activates it. The 
G-subunits dissociate, and α-subunits stimulate adenylate cyclase (AC) to forma-
tion of cyclic adenosine 3′,5′-monophosphate (cAMP). It is stated that cAMP acts as 
a catalyst for the process of activation of protein kinase A (PKA) and due to that it 
is involved in control of muscle tone. On the other hand cAMP inhibits the release 
of cytosolic calcium ion (Ca2+) in the smooth muscle cells, which leads to vascular 
relaxation (vasodilation) [8, 15].
Although the β2-ARs activated by β2-ARs agonists mostly influence the blood 
vessels (mainly arterioles and coronary arteries), they can also act in the heart 
and kidney. In the atrial and ventricular myocardium, stimulation of β2-ARs leads 
to increase in cardiac muscle contractility or relaxation, whilst in the kidneys it 
stimulates the release of renin, what it turn influences activation of the renin-
angiotensin-aldosterone system [1, 8].
The primary role of the β-ARs in the heart is to coordinate the heart rate and 
contractility in response to the SNS neurotransmitters [6]. β1-AR is the most 
abundant subtype accounting for 75–80% in a healthy myocardium [6]. Around 
15–18% of cardiomyocyte β-ARs are β2-AR whilst the remaining 2–3% of β-AR 
density is composed of β3-ARs [6]. Activation of β1-ARs and to a smaller degree 
β2-ARs, leads to an increase in cardiac contractility and an accelerated cardiac rate. 
Stimulation of the two predominate β-ARs also increases impulse transmission via 
the atrioventricular node [6]. The activation of cardiomyocyte β1- and β2-ARs also 
leads to a significant increase in free intracellular Ca2+ concentration [6]. Calcium 
is a secondary messenger in many biological systems. In cardiomyocytes, calcium 
affects ion channels which regulate ionic currents, impacting upon action potentials 
and muscle contractility [16]. Β3-AR appears to illicit an opposite effect on cardiac 
function to that induced by β1- and β2-ARs in that it acts to prevent cardiac hyper-
stimulation from NE and Epi (Table 1) [6].
Constant elevation of catecholamines leading to β-AR signalling changes results 
in overstimulation of cardiac function [1]. Reducing the β-AR activity is vital to 
alleviate the risk of long-term cardiac tissue damage such as cardiomyopathy. 
Propanolol was discovered to be a β-AR antagonist in 1964, a so called β-blocker. 
Alprenolol and Practolol β-blockers have also been used for the management of 
heart failure [1]. β-Blockers function to overcome the harmful effects of norepi-
nephrine which overstimulate the β1-AR, leading to a reduction in cardiac workload 
[1]. The most recently used β-blockers bisoprolol and carvedilol target both β1- and 
β2-ARs produce a survival benefit for heart failure patients [1]. In rats β2-AR ago-
nists (fenoterol and zinterol) were shown to reduce progression of left ventricular 
modelling in dilated cardiomyopathy in addition to decreasing myocardial cell 
death [17]. In a later study the same group determined that in a rat model of dilated 
ischemic cardiomyopathy, Metoprolol, a β1-AR blocker, action is enhanced when 
given in combination with the β2-AR agonist fenoterol [18].
Cardiac Diseases
4
The β2-ARs have also been directed implicated in patients with ischaemic 
cardiomyopathy. A Gln27Glu polymorphism of β2-AR was discovered in a study 
investigating 155 people with heart failure of ischaemic aetiology with impaired 
Left Ventricular Ejection Fraction ≤35% [19]. Three allele categories were discov-
ered, the most common genotype in heart failure was Gln27Gln, and the least com-
mon was Glu27Glu, whilst Gln27Glu was not significantly different between heart 
failure and control subjects. The study concluded that the Glu allele was associated 
with lower myocardial infarction rate and highlighted that patient response to 
β-blockade therapy may be altered [19]. Likewise β1-AR (Ser49Gly, Arg389Gly) 
and β2-AR (Arg16Gly, Gln27Glu, Thr164Ile) polymorphisms did not alter in a 
Polish cohort study of patients with idiopathic dilated cardiomyopathy [20]. It is 
of interest that in patients with Takotsubo cardiomyopathy, β-AR polymorphisms 
(β1-AR (Gly389Arg) and β2-AR (Arg16Gly and Gln27Glu)) were significantly dif-
ferent to controls but similar to patients with ST-elevation myocardial infarction 
[21]. Work combining beta-blockers with ACE-inhibitors/angiotensin receptor 
blockers over the years using meta-analysis data has shown reduced recurrence of 
the disorder [22].
A murine model depleting levels of β2-ARs also resulted in diabetic cardiomy-
opathy in vivo and reduced β2-ARs in cardiomyocytes grown under in hyperglyce-
mic conditions [23]. Conversely, overexpression of β2-ARs (by 300 fold) in mice 
showed that over time severe cardiomyopathy was observed, resulting in interstitial 
fibrosis, loss of myocytes and myocyte hypertrophy. In the majority of the 81% of 
mice that died within 15 months, heart failure was observed [24]. These results were 
similar to other transgenic overexpression mouse lines. The authors hypothesised 
that a number of mechanisms from activation of growth or transcriptional factors, 
cross-talk with other pathways, necrosis or apoptosis of cardiac myocytes and/or 
high heart rates limiting energy supply.
The human heart also possesses α1 adrenoreceptors (α1-AR) although in a 
smaller quantity to the β-ARs [25]. The α1-ARs are expressed in the heart, both the 
α1A-and α1B-AR subtypes are expressed in human myocytes, and have been shown 
to regulate contractility [26, 27]. The α1-ARs combine with the Gq/11 family of G 
proteins, in turn activating phospholipase C. The secondary messenger IP3 binds 
to receptors on the membrane of the sarcoplasmic reticulum, triggering the release 
of intracellular Ca2+ [6]. The raised Ca2+ level leads an increase in vasoconstriction 
[6]. The coupling of α1-ARs to the Gq/11 family of G proteins also produces DAG and 
subsequent protein kinase C [6].
Action β1-AR β2-AR Β3-AR
Heart muscle contraction Yes Yes
Increases cardiac output Yes Yes
Increases heart rate in SA node Yes Yes
Increases atrial contractility Yes Yes
Increases contractility and automaticity of ventricular muscle Yes Yes
Dilates muscular blood vessels Yes Yes
Increases perfusion in blood vessels Yes
Metabolism/lipolysis/thermogenesis Yes
Prevent cardiac hyperstimulation Yes
Table 1. 
Actions of β-adrenergic receptors.
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In heart failure the α1-ARs may offer a protective benefit to maintain cardiac 
inotropy, preventing cardiomyocyte apoptosis and maladaptive cardiac remodelling 
[6]. Although a small study, loss of β1-AR and no change in β2-AR levels in end-stage 
dilated cardiomyopathy patients was observed alongside a loss of α1A-ARs [28]. 
Although the role of β1-AR in heart failure has long been described, this interaction 
between the α-ARs was novel as the few previous studies had shown no change 
or increases in α-ARs binding but these were different types of heart failure. In 
addition a total of 26 proteins of interest were also identified in the cardiomyopathy 
patients, some of which have been linked to G-protein coupled receptor signal-
ling and desensitisation [28]. Prostatic binding protein levels decreased whereas 
increases in ANP32A and clathrin were noted. Also of interest are Takotsubo 
cardiomyopathy (also known as stress cardiomyopathy) patients. This condition is 
often reversible, and two studies have shown that several β1-AR and α2c-AR poly-
morphisms were not implicated in Takotsubo cardiomyopathy [29, 30].
2.2 Angiotensin II type 1 and 2 receptors
Angiotensin II (AngII) is an important protein in the renin-angiotensin system 
(RAS). In the bloodstream renin converts angiotensinogen (derived from liver) into 
angiotensin I, which in turn is transformed into AngII by angiotensin converting 
enzyme (ACE) [14, 31, 32]. AngII can be also secreted in some local tissues includ-
ing within the brain, heart, arteries and kidney [32].
The Angiotensin II type 1 and 2 receptors (AT1 and AT2 receptors) belong to the 
wide family of G-protein coupled receptors (GPCRs), members of which have seven 
transmembrane spanning domains and is the biggest member of the human genome 
[31, 33]. The distinction and classification of AT1 and AT2 receptors is based on 
their varied affinity for different non-peptide antagonists [34]. Moreover the 
AT1 and AT2 receptors differ between each other in their number of amino acids, 
tissue-specific expression and mechanisms of signal transferring [13]. Both of these 
receptors occur in all mammals and bind a peptide hormone angiotensin II (AngII), 
which is the most important effector in the RAS [32].
The main role of angiotensin becomes apparent in the cardiovascular and endo-
crine systems where it regulates blood pressure and hydro-electrolytic homeostasis 
[32, 33]. It is stated that the main physiological functions of AngII (vasoconstriction, 
aldosterone secretion, renal regulations cellular dedifferentiation and proliferation) 
are mediated mostly by the AT1 subtype of angiotensin receptor [14, 31, 33–36]. In 
humans, the genes encoding AT1 receptors are mapped on chromosome 3q21–3q25 
[37]. The AT1 receptors consist of 359 amino acids, with a molecular weight of 
41 kDa, and their amino sequence reveals 20–35% homology with other GPCRs [31].
In adult mammals, AT1 receptors are mainly expressed in kidney (glomeruli, 
proximal tubules, vasculature, medullary interstitial cells), adrenal glands (cortex, 
medulla), heart (myocardium, ganglia, conduction system), brain (circumven-
tricular organs, thalamus, basal ganglia, cerebellar cortex, medulla oblongata) and 
vasculature (smooth muscles, adventitia) [32, 38]. Rats and mice can have two 
isoforms of the Angiotensin II 1 receptor: AT1A and AT1B with amino acid sequence 
convergence seen at 94% [14, 31, 33, 34]. AT1A receptors are present predominantly 
in vascular smooth muscle, liver, lung and kidney whilst AT1B receptors occur 
mainly in the adrenal gland and anterior pituitary [31, 34, 38]. The rodent AT1A and 
AT1B receptor genes are situated on chromosomes 17 and 2 respectively [38].
The activity of angiotensin II through AT1 receptors should be considered in 
physiological and pathophysiological conditions. The physiological signalling path-
way involves the renin-angiotensin-aldosteron system and leads to changes in blood 
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pressure primarily through vasoconstriction of arteries and arterioles, secretion of 
aldosterone from adrenal gland and sodium reabsorption by via the kidney tubules 
[32]. Ang II mediates vasoconstriction through the IP3/DAG pathway, which uses 
Gq/11 protein-coupled receptors. Gq/11 activates phospholipase C (PLC), which 
hydrolyses phosphatidylinositol 4,5-bisphosphate (PIP2) and produces diacyl glyc-
erol (DAG) and inositol trisphosphate (IP3). IP3 causes an increase in intracellular 
calcium whilst DAG activates protein kinases C [31]. The increased concentration 
of calcium (Ca2+ ions) within vascular smooth muscle cells leads to vasoconstriction 
which results in an increase in blood pressure or may causing a localised reduction 
in blood flow in some specific tissues [32, 36]. AngII acting through the AT1 recep-
tors located in the zona glomerulosa of the adrenal gland stimulates the release of 
aldosterone [32]. Aldosterone then acts on the distal convoluted tubules and the 
cortical collecting ducts in kidney, firstly causing sodium (Na+) retention, leading 
to increased peripheral resistance and secondly causing resorption of water from 
urine which also increases extracellular fluid volume. Both of these mechanisms 
lead to an elevation in arterial pressure [32].
Considering the pathological conditions, the activity of AngII through AT1 
receptors may induce the proliferation of vascular smooth muscle cells which in 
turn promotes myocyte hypertrophy and causes vascular fibrosis. Proliferation of 
smooth muscle cells is also involved in the initial stages of atherosclerotic plaques 
formation in arteries [32]. AngII binding to AT1 receptors also activate the mul-
tiple intracellular signalling pathway that promotes atherosclerosis. The pathway 
includes oxidative stress, inflammation, endothelial dysfunction, tissue remodel-
ling, proliferation fibrosis, thrombosis and autostimulation. Moreover AngII 
may participate in the process of atherosclerosis lesion formation as it stimulates 
the release of endothelin-1 (ET-1) from the endothelial cells [32]. In addition to 
inducing proliferation and atherosclerotic plaques formation, AngII may have an 
effect on the developing/developed plaques. Atherosclerotic plaque stability and 
disruption is in turn associated with matrix metalloproteinase (MMP) enzymes, 
the production of which can be stimulated by AngII [32]. The MMPs are inhibited 
by tissue inhibitors of metalloproteinases (TIMPs) and disruption of the balance 
between MMPs and TIMPs may lead to cardiovascular diseases [37, 39]. Moreover, 
in pathological states, the activation of AT1 receptor by AngII may cause vascular 
remodelling and growth by expression of autocrine growth factors (including 
fibroblast growth factor and platelet-derived growth factor) in vascular smooth 
muscle cells [32, 40].
The activation of AT2 receptors by AngII has an opposite effect to AT1 receptors. 
It means that the functions of AngII mediated by AT2 receptors are vasodilation, 
natriuresis and inhibition of cellular growth and proliferation [14]. Genes encod-
ing AT2 receptors are localised on chromosome Xq22-q2 [13, 31]. The molecular 
weight of AT2 receptors is approximately 41 kDa and they consist of 363 amino 
acids [13, 41].
AT2 receptor expression has been localised in both foetal and adult tissues. 
In foetuses, expression of AT2 receptors is intense, especially in a cardiovascular 
system [13]. In adult mammals the expression of AT2 receptor is still observed in 
heart (mainly in myocardium) and renal blood vessels but is significantly lower 
than before birth [13, 38]. Expression of AT2 receptors has been also noted in the 
adrenal gland (cortex and medulla), brain (thalamus, cerebellar cortex), mesenteric 
and uterine arteries [38, 42].
It is stated that the AT2 receptor acts to stabilise blood pressure by control-
ling vascular tone by vasodilation [13]. In this action the AT2 receptor together 
with other GPCR family B2 receptors for bradykinin form a stable functional 
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heterodimer, which causes the increase of nitric oxide (NO) and stimulating cyclic 
guanosine monophosphate (cGMP) synthesis. The cGMP contributes to relaxation 
of smooth muscles, which in large veins, large arteries, and smaller arterioles leads 
to vasodilation and causes decreased blood pressure. It has also been suggested that 
activation of AT2 receptors by AngII may inhibit arterial and myocardial hypertro-
phy and fibrosis in the ageing heart and vasculature.
Therefore AngII exerts its influence via the activation of the Angiotensin II 
type I receptor (AT1R), a 7TMR located in vascular smooth muscle as well as in the 
kidneys, brain and adrenal glands in an effort to maintain sodium/water homeosta-
sis and moderate vasoconstriction [1]. AT1R acts to control arterial pressure, blood 
volume and to encourage growth and proliferation through the activation of cellular 
signalling mechanisms [15]. The AT1R is a Gq/11 coupled receptor [25]. Stimulation 
by AngII leads to the activation of phospholipase C-β and the release of DAG and 
IP3, followed by the activation of protein kinase C and movement of intracellular 
calcium [3]. AT1Rs are upregulated in cardiac tissue in response to hypertrophic 
triggers, encouraging unfavourable cardiac remodelling in heart failure [9]. These 
complex roles have resulted in a number of angiotensin receptor blockers (ARBs) 
and angiotensin converting enzyme (ACE) inhibitors to be developed and used as 
cardiovascular treatments. ARBs and ACE inhibitors have demonstrated a reduction 
in deleterious left ventricular remodelling, such as hypertrophy and myocardial 
stiffness which as associated with heart failure [6]. ACE inhibitors alongside 
antagonists of the AT1R, the -sartans, have become one of the main pharmaceutical 
treatments for hypertension and cardiovascular disease [1]. Commonly used ARBs 
include Losartan, Valsartan and Candesartan [43]. ARBs function to interfere with 
the renin-angiotensin system by preventing the binding of AngII to AT1R. This inhi-
bition of AngII result in vascular smooth muscle relaxation, a reduction in cellular 
hypertrophy, and a decrease in plasma volume resulting from an increase in salt and 
water excretion [43].
A number of advances in terms of cardiomyopathy and ANGII and its recep-
tors have been made in the last few years. In terms of cardiomyopathy, the AngII 
receptor inhibitor LCZ696 has been shown to inhibit extracellular signal-regulated 
kinase (ERK), resulting in increased survival in pregnancy-associated cardio-
myopathy mice. The authors indicated that by reducing cardiac hypertrophy, 
fibrosis and apoptosis it could act as a potential treatment for this cardiomyopathy 
[44]. Another study showed that this angiotensin receptor-neprilysin inhibitor 
reduced inflammation, oxidative stress and apoptosis in vitro and in vivo [45]. It 
has also been stated that in end-stage hypertrophic cardiomyopathy, the modern 
Angiotensin receptor neprilysin inhibitor treatments are both safe and effective 
[46]. Angiotensin-converting enzyme 2 (ACE2) has also showed therapeutic 
potential when looking at doxorubicin-induced cardiomyopathy rat models [47]. 
The enzyme reduced apoptosis, inflammatory responses, and oxidative stress 
and reduced mortality and myocardial fibrosis whilst improving ventricular 
remodelling and cardiac function. They also showed activation of the AMPK and 
PI3K-AKT pathways, inhibition of the ERK pathway, and decreased TGF-β1 [47]. 
Sulforaphane, which activates nuclear factor erythroid 2-related factor 2 (Nrf2), 
has also been shown to present angiotensin II-induced cardiomyopathy via Akt/
GSK-3ß/Fyn -mediated Nrf2 activation [48].
Aldehyde dehydrogenase 2 (ALDH2) has also been shown to protect against 
alcoholic cardiomyopathy [49]. By decreasing angiotensinogen and AngII this 
cardioprotective enzyme inhibited local RAS in mice by inhibiting the p38 
MAPK/CREB pathway. In another form of cardiomyopathy, hypertrophic, ACE 
inhibitors angiotensin-receptor blockers have been used to try and regulate the 
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renin-angiotensin-aldosterone system [50]. This has resulted in patients having a 
lower risk of developing atrial fibrillation which is associated with hypertrophic 
cardiomyopathy.
Much work has looked into polymorphisms in the angiotensin-converting 
enzyme gene itself in relation to hypertrophic cardiomyopathy risk; however, 
the studies have sometimes shown conflicting results. A systematic review and 
meta-analysis indicated that the ACE insertion/deletion (I/D of 287 base pairs in 
intron 16) polymorphism was probably a risk for hypertrophic cardiomyopathy 
[51]. People with the DD genotype have increased levels of ACE and angiotensin 
II and therefore more hypertrophy and fibrosis, as seen in other situations where 
their levels increase. Although many of the 1 in 500 people affected by hypertro-
phic cardiomyopathy have mutations in the genes coding for sarcomeric proteins, 
polymorphisms in the components of the RAS are implicated. ACE DD has also 
been associated with dilated cardiomyopathy patients, angiotensin receptor type 
11166CC genotypes with both hypertrophic and dilated cardiomyopathy and the 
235TT genotype of angiotensinogen (M235T) is associated with hypertrophic, 
dilated and restrictive cardiomyopathy [52].
Overstimulation of AngII has also been reported in dilated cardiomyopathy [53] 
and AT1R overexpression resulted in female mice being more affected (especially 
in terms of heart failure and increased mortality) than males [53]. In particular, 
ventricular hypertrophy and dilation and changes in Ca2+ activity and homeostasis 
were observed, and these reflect that clinical observations that dilated cardiomy-
opathy can be exacerbated in women in comparison to men. This can also be linked 
to oestrogen which increases angiotensinogen and decreased renin, ACE and AT1R 
expression but of course following menopause these effects are lost [54].
Much has been investigated in relation to the use of ACE inhibitors in patients 
with ischemic cardiomyopathy. Much work has been carried out in patients with 
an ejection fraction of less than 40% with these enzymes working well. More 
recently attention has turned to those with an ejection fraction of more than 40% 
who were studied less. In patients with 40–50% ejection fraction, the ACE inhibi-
tors were seen to reduce the risk of mortality, nonfatal myocardial infarction and 
stroke by 21% [55].
2.3 Endothelin-1 (ET-1) receptor
There are three different forms of 21-amino acid peptides, which belong to the 
endothelin peptide family: ET-1, ET-2, and ET-3 [56]. They vary in biological func-
tion and may affect blood vessels as well as other tissues both within and outside of 
the cardiovascular system [56]. The predominant form of endothelin peptide is an 
isopeptide ET-1 with potent vasoconstrictor and proliferative properties [57]. ET-1 
is synthetized by endothelial cells, airway smooth muscles cells, cardiomyocytes, 
macrophages, leukocytes and mesangial cells [57].
There are two subtypes of receptors which are mediated by endothelin, known 
as Endothelin Type A receptor (ETA) and type B (ETB) [57]. Although mediated 
by the same peptide agonist, activity of these two subtypes is usually opposite, as 
the ETA receptor promotes vasoconstriction, growth, and inflammation whilst ETB 
receptors may cause both vasoconstriction and vasodilation and also increases in 
sodium excretion and inhibition of growth and inflammation [57–59].
The potential to bind with ETA receptors is the same for ET-1 and ET-2 
endothelin but lower for ET-3 endothelin, whilst the potential binding rate 
with ETB receptors is equal for every form of endothelin [57, 58]. In people the 
genes responsible for expression of the ETA receptors are situated on chromo-
some 4q31.22-q31.23, whilst genes encoding ETB receptors are mapped onto 
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chromosome 13q22.3 [60]. The molecular weight of the ETA and ETB receptors are 
48 and 50 kDa respectively [61, 62]. The human 427 amino acid long ETA recep-
tors and 442 amino acid long ETB receptors are approximately 64% homologous 
[58]. The homology of ETA and ETB receptors in humans and other mammalian 
species is between 88% and 97% [58].
ETA receptors are expressed predominantly in the heart (coronary vasculature 
and cardiomyocytes), lungs (pulmonary artery), kidney (renal artery, affer-
ent and efferent arteriole, cortical vasculature, mesangial cells), brain (cerebral 
vasculature) and adrenal gland. ETB receptors also occur in the heart (coronary 
vasculature and cardiomyocytes), lungs (pulmonary artery), kidney (renal artery, 
afferent and efferent arteriole, medullar vasculature), brain (cerebral vasculature) 
and adrenal gland [63].
The ETA receptors mediated by ET-1 endothelin in vascular smooth muscle cells 
promoting vasoconstriction, hypertension, hypertrophy, fibrosis and inflammatory 
changes, including atherosclerosis and due to that has activity similar to the AT1 
receptors mediated by AngII [63]. The vasoconstrictive pathway of ETA receptors 
includes: Coupling to phospholipase C (PLC) via GTP-binding protein, phospholi-
pase C activation, phosphatidyl inositol hydrolysis, inositol 1,4,5 triphosphate (IP3) 
generation and 1,2-diacylglycerol (DCG) accumulation. Inositol triphosphate is a 
signalling molecule that leads to mobilisation of Ca2+ from intra- and extra-cellular 
sources resulting in long-lasting vasoconstriction [56, 64].
The ETB receptors mediated by ET-1 endothelin in the vascular endothelium are 
involved in the clearance of ET-1 and stimulate vasodilation due to the nitric oxide 
and cyclooxygenase metabolites production, which also exert vasorelaxant effects 
on the underlying smooth muscle. Moreover, the ETB receptors have a natriuretic 
action causing sodium and water resorption from the distal tubules and collecting 
ducts in the kidney. The ETB receptors, which occur in smooth muscle cells, addi-
tionally act as vasoconstrictors [57, 63, 64].
In the last few years research into endothelin has progressed the information 
known about links to cardiomyopathies. Some of the early published studies 
showed that ET-1 and its receptor either played a causative role in hypertrophic 
cardiomyopathy, idiopathic dilated cardiomyopathy and uremic cardiomyopathy 
or could be a marker [65–68]. Indeed work in cats has even reflected the increased 
ET-1 levels in cases of hypertrophic, dilated, restrictive and unclassified cardio-
myopathy [69]. More work has now been carried out into other cardiomyopathies 
and the potential mechanisms of action. Much like ACE2, the endothelin receptor 
blocker bosentan has been shown to inhibit doxorubicin-induced cardiomyopa-
thy in a rodent model [70]. This study looked at the receptor blocker as elevated 
levels of ET-1 were discovered in doxorubicin treated patients. The in vitro studies 
indicated that activation of the epidermal growth factor (EGF) receptor and the 
MEK1/2-ERK1/2 cascade were possible mechanisms of action [70]. A good review 
looking at endothelin-1 and atrial cardiomyopathy, published in 2019 brings 
together the information in this area. The work over the years has indicated that 
endothlin-1 plays an active role affecting Ca2+ levels, via the ET-1-superoxide-
MMP9 cascade and via apoptosis, resulting in both electrical and anatomical 
remodelling [71].
Not only is endothelin-1 a potential therapeutic route but it also shows promise 
in predicting patient outcomes. A recent study investigating new-onset atrial fibril-
lation in patients with obstructive hypertrophic cardiomyopathy has shown that 
elevated pre-operative levels may indicate increased likelihood of atrial fibrillation 
[72]. Big endothelin-1, the precursor of endothelin-1 has also been shown to be use-
ful when predicting prognosis for hypertrophic cardiomyopathy patients and the 
authors have suggested that it should be added to marker panels [73, 74]. Endothelin 
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1 has also been implicated as a modifier in dilated cardiomyopathy. With variations 
including the rare G > A and a C > T at c.90 seen in dilated cardiomyopathy patients 
and EDN1 polymorphisms linked to increased risk of the disorder, likely by altered 
the stability of the protein [75]. A model of diabetic cardiomyopathy in rats also 
showed that plasma endothelin-2 levels were higher that controls and that overex-
pression of the protein results in a more severe phenotype [76].
2.4 Muscarinic receptors
Cardiac function is controlled by the SNS and parasympathetic nervous system 
(PNS). Parasympathetic vagal nerves are distributed throughout all areas of the 
heart, particularly in the ventricles [77]. Cardiac muscarinic receptors are activated 
by acetylcholine, having been stimulated by vagal nerve activation. The muscarinic 
acetylcholine receptors (M-ChR) are glycoproteins belonging to the 7TMR super-
family [77]. The M2 subtype of M-ChR are the most prevalent group within the 
mammalian heart and their function is opposed to the β-ARs in that they cause a 
reduction in myocardium contractility and a lower cardiac rate [10]. M-ChR exert 
their influence on the myocardium via the Gα1-coupled receptors which inhibit 
adenylyl cyclase whilst the Gβγ dimer impedes the activity of potassium channels 
in the sinoatrial node [1]. M-ChR can also exert an effect over Ca2+ channels [77] 
affecting cardiac contractility.
Heart failure patients demonstrate an increase in M2 muscarinic receptor 
density, with activated M2 receptors encouraging an inotropic response [9]. One 
study using serum from a patient showed that when autoantibodies to the musca-
rinic receptors and β-ARs were activated it resulted in cardiomyopathy and atrial 
tachyarrhythmias [78]. Along a similar line, autoantibodies against β1-ARs have 
been shown to cause sudden death in idiopathic dilated cardiomyopathy patients 
[79]. Antibodies to β-ARs have been discovered in people with idiopathic dilated 
cardiomyopathy, even leading to the suggestion of a form of ‘adrenergic cardio-
myopathy’ [80]. In addition autoantibodies against muscarinic receptors have also 
been noted in cases of peripartum cardiomyopathy [81], dilated cardiomyopathy 
[82–85], and M2-muscarinic acetylcholine receptor autoantibodies have been 
implicated in playing a role in atrial fibrillation in dilated cardiomyopathy patients 
[86] Similar increases were not observed in patients with Takotsubo cardiomy-
opathy [87] or in rats with cirrhotic cardiomyopathy [88]. Autoantibodies against 
cardiomyocytes, β1- or β2-ARs or M2 muscarinic receptors were not noted in 20 
people with Takotsubo cardiomyopathy in comparison to healthy controls, or in 
rats with cirrhotic cardiomyopathy.
3. Conclusions
The superfamily of 7TMRs includes receptors for hormones, neurotransmitters 
and ion channels, and are critical to mediate physiological and cellular processes 
[1, 2]. This chapter has investigated adrenoreceptors (both α- and β-adrenergic 
receptors) and the components of the renin-angiotensin system (RAS) especially 
AngII, ACE and the AT1 and AT2 receptors. The chapter has also looked at endo-
thelin-1 (ET-1) and its receptor, and precursor Big endothelin-1 and finally the 
muscarinic receptors. By looking at their numerous effects in both healthy and 
diseased vasculature and cardiac disorders, especially cardiomyopathies, it can 
be seen that there are wide ranging effects. Developing these 7TMRs as markers 
of disease, for prognosis, diagnosis and therapeutic treatments is becoming more 
important as their many roles as being uncovered in the cardiovascular system.
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